"Access to Medicine Index 2016," Nov 2016

…The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. It highlights best and innovative practices, and areas where progress has been made and where action is still required…The 2016 Index used a framework of 83 metrics to measure company performances relating to 51 high-burden diseases in 107 countries…The Index analyses data gathered via a detailed survey of pharmaceutical company behaviour regarding access to medicine…The 2016 Index has a sharper focus on whether companies target their actions toward the people with the greatest need for better access to medicine. For example, in pricing, the Index examines whether companies price products fairly in the countries with the greatest need for those specific products. In R&D, it looks at whether companies are developing products that are urgently needed, yet offer little commercial incentive…

[Also refers to AbbVie, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Co., Eisai Co., Eli Lilly & Co., Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche Holding, Sanofi, and Takeda Pharmaceutical.]